These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

599 related items for PubMed ID: 18614347

  • 1. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C.
    Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
    [Abstract] [Full Text] [Related]

  • 2. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
    Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, TORCH investigators.
    N Engl J Med; 2007 Feb 22; 356(8):775-89. PubMed ID: 17314337
    [Abstract] [Full Text] [Related]

  • 3. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
    Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, Pasma HR, Hensing CA, Creutzberg EC, COSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) Study Group.
    Thorax; 2005 Jun 22; 60(6):480-7. PubMed ID: 15923248
    [Abstract] [Full Text] [Related]

  • 4. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.
    Kardos P, Wencker M, Glaab T, Vogelmeier C.
    Am J Respir Crit Care Med; 2007 Jan 15; 175(2):144-9. PubMed ID: 17053207
    [Abstract] [Full Text] [Related]

  • 5. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
    Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P, TRISTSAN study group.
    Thorax; 2005 Apr 15; 60(4):301-4. PubMed ID: 15790985
    [Abstract] [Full Text] [Related]

  • 6. EXCEL: A randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma.
    Dahl R, Chuchalin A, Gor D, Yoxall S, Sharma R.
    Respir Med; 2006 Jul 15; 100(7):1152-62. PubMed ID: 16675212
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.
    Earnshaw SR, Wilson MR, Dalal AA, Chambers MG, Jhingran P, Stanford R, Mapel DW.
    Respir Med; 2009 Jan 15; 103(1):12-21. PubMed ID: 19010652
    [Abstract] [Full Text] [Related]

  • 8. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
    Cowie RL, Boulet LP, Keith PK, Scott-Wilson CA, House KW, Dorinsky PM.
    Clin Ther; 2007 Jul 15; 29(7):1390-402. PubMed ID: 17825690
    [Abstract] [Full Text] [Related]

  • 9. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
    Hagedorn C, Kässner F, Banik N, Ntampakas P, Fielder K.
    Respir Med; 2013 Apr 15; 107(4):542-9. PubMed ID: 23337300
    [Abstract] [Full Text] [Related]

  • 10. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD.
    Hanania NA, Crater GD, Morris AN, Emmett AH, O'Dell DM, Niewoehner DE.
    Respir Med; 2012 Jan 15; 106(1):91-101. PubMed ID: 22040533
    [Abstract] [Full Text] [Related]

  • 11. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM, Akazawa M, Dalal A, Simoni-Wastila L.
    Am J Geriatr Pharmacother; 2008 Aug 15; 6(3):138-46. PubMed ID: 18775388
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study.
    Maspero J, Guerra F, Cuevas F, Gutierrez JP, Soto-Ramos M, Anderton S, Mechali D, Chan R, Pedersen S.
    Clin Ther; 2008 Aug 15; 30(8):1492-504. PubMed ID: 18803991
    [Abstract] [Full Text] [Related]

  • 13. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study.
    Jung KS, Park HY, Park SY, Kim SK, Kim YK, Shim JJ, Moon HS, Lee KH, Yoo JH, Lee SD, Korean Academy of Tuberculosis and Respiratory Diseases study group, Korea Chronic Obstructive Pulmonary Disease study group.
    Respir Med; 2012 Mar 15; 106(3):382-9. PubMed ID: 21975275
    [Abstract] [Full Text] [Related]

  • 14. Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD.
    Schermer TR, Albers JM, Verblackt HW, Costongs RJ, Westers P.
    Fam Pract; 2007 Apr 15; 24(2):181-8. PubMed ID: 17251178
    [Abstract] [Full Text] [Related]

  • 15. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes.
    Anzueto A, Ferguson GT, Feldman G, Chinsky K, Seibert A, Emmett A, Knobil K, O'Dell D, Kalberg C, Crater G.
    COPD; 2009 Oct 15; 6(5):320-9. PubMed ID: 19863361
    [Abstract] [Full Text] [Related]

  • 16. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.
    Zheng JP, Yang L, Wu YM, Chen P, Wen ZG, Huang WJ, Shi Y, Wang CZ, Huang SG, Sun TY, Wang GF, Xiong SD, Zhong NS.
    Chest; 2007 Dec 15; 132(6):1756-63. PubMed ID: 17951625
    [Abstract] [Full Text] [Related]

  • 17. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
    Partridge MR, Schuermann W, Beckman O, Persson T, Polanowski T.
    Ther Adv Respir Dis; 2009 Aug 15; 3(4):1-11. PubMed ID: 19734176
    [Abstract] [Full Text] [Related]

  • 18. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
    Lindberg A, Szalai Z, Pullerits T, Radeczky E.
    Respirology; 2007 Sep 15; 12(5):732-9. PubMed ID: 17875063
    [Abstract] [Full Text] [Related]

  • 19. Initial treatment of symptomatic mild to moderate bronchial asthma with the salmeterol/fluticasone propionate (50/250 microg) combination product (SAS 40023).
    Baumgarten C, Geldszus R, Behre U, Peslis N, Trautmann M, Viani-Initial Study Group.
    Eur J Med Res; 2002 Jan 29; 7(1):1-7. PubMed ID: 11827834
    [Abstract] [Full Text] [Related]

  • 20. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
    Kurashima K, Hara K, Yoneda K, Kanauchi T, Kagiyama N, Tokunaga D, Takayanagi N, Ubukata M, Sugita Y.
    Respirology; 2009 Mar 29; 14(2):239-44. PubMed ID: 19210650
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.